Theravance Biopharma, Inc. (TBPH)
NASDAQ: TBPH · Real-Time Price · USD
11.55
+0.33 (2.94%)
Jul 9, 2025, 3:04 PM - Market open
Theravance Biopharma Employees
Theravance Biopharma had 97 employees as of December 31, 2024. The number of employees decreased by 2 or -2.02% compared to the previous year.
Employees
97
Change (1Y)
-2
Growth (1Y)
-2.02%
Revenue / Employee
$672,845
Profits / Employee
-$601,371
Market Cap
577.52M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
TBPH News
- 13 days ago - Theravance Biopharma Announces Approval of YUPELRI® (revefenacin) by China's NMPA - PRNewsWire
- 5 weeks ago - Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million - PRNewsWire
- 2 months ago - Theravance Biopharma to Participate in an Upcoming Investor Conference - PRNewsWire
- 2 months ago - Theravance Biopharma, Inc. (TBPH) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Theravance Biopharma Announces Ampreloxetine Presentations at the International MSA Congress - PRNewsWire
- 2 months ago - Theravance Biopharma, Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update - PRNewsWire
- 2 months ago - Theravance to Present Analyses of Ampreloxetine and Neurogenic Orthostatic Hypotension at the 2025 International MSA Congress - PRNewsWire
- 2 months ago - Theravance Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025 - PRNewsWire